1. Home
  2. SPRY vs CASH Comparison

SPRY vs CASH Comparison

Compare SPRY & CASH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SPRY
  • CASH
  • Stock Information
  • Founded
  • SPRY 2015
  • CASH 1954
  • Country
  • SPRY United States
  • CASH United States
  • Employees
  • SPRY N/A
  • CASH N/A
  • Industry
  • SPRY Biotechnology: Pharmaceutical Preparations
  • CASH Major Banks
  • Sector
  • SPRY Health Care
  • CASH Finance
  • Exchange
  • SPRY Nasdaq
  • CASH Nasdaq
  • Market Cap
  • SPRY 1.8B
  • CASH 1.7B
  • IPO Year
  • SPRY N/A
  • CASH N/A
  • Fundamental
  • Price
  • SPRY $11.62
  • CASH $79.47
  • Analyst Decision
  • SPRY Strong Buy
  • CASH Buy
  • Analyst Count
  • SPRY 4
  • CASH 2
  • Target Price
  • SPRY $28.75
  • CASH $91.00
  • AVG Volume (30 Days)
  • SPRY 2.3M
  • CASH 161.0K
  • Earning Date
  • SPRY 08-13-2025
  • CASH 10-22-2025
  • Dividend Yield
  • SPRY N/A
  • CASH 0.25%
  • EPS Growth
  • SPRY N/A
  • CASH 4.46
  • EPS
  • SPRY N/A
  • CASH 6.92
  • Revenue
  • SPRY $112,339,000.00
  • CASH $733,796,000.00
  • Revenue This Year
  • SPRY N/A
  • CASH $18.96
  • Revenue Next Year
  • SPRY $182.40
  • CASH $5.11
  • P/E Ratio
  • SPRY N/A
  • CASH $11.49
  • Revenue Growth
  • SPRY 22367.80
  • CASH 5.46
  • 52 Week Low
  • SPRY $10.00
  • CASH $62.79
  • 52 Week High
  • SPRY $18.90
  • CASH $86.00
  • Technical
  • Relative Strength Index (RSI)
  • SPRY 25.12
  • CASH 58.79
  • Support Level
  • SPRY $13.32
  • CASH $75.77
  • Resistance Level
  • SPRY $14.00
  • CASH $76.01
  • Average True Range (ATR)
  • SPRY 1.00
  • CASH 1.86
  • MACD
  • SPRY -0.30
  • CASH 0.67
  • Stochastic Oscillator
  • SPRY 9.88
  • CASH 83.21

About SPRY ARS Pharmaceuticals Inc.

ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.

About CASH Pathward Financial Inc.

Pathward Financial Inc is a unitary savings and loan holding company. It's a wholly owned full-service banking subsidiary of Meta Financial, is both a community-oriented financial institution offering a variety of financial services to meet the needs of the communities it serves, and a payments company providing services on a nationwide basis. It operates through three reportable segments: Consumer: The Consumer segment includes the Partner Solutions business line, which collaborates with partners to navigate payment and lending needs; Commercial: The Commercial segment includes the Company's Commercial Finance business line, which helps businesses access funds needed to launch, operate, and grow; and Corporate Services. The majority of the revenue is generated from Consumer segment.

Share on Social Networks: